Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4376870 | 1.00 | TLR4 (0.35) | TLR4CYP2C9 | |
| SCHEMBL7858209 | 0.94 | CYP2C9 (0.36) | CYP2C9 | |
| SCHEMBL7858208 | 0.94 | CYP2C9 (0.36) | CYP2C9 | |
| SCHEMBL7858210 | 0.94 | CYP2C9 (0.36) | CYP2C9 | |
| SCHEMBL8456171 | 0.85 | TRPA1 (0.33) | — | |
| SCHEMBL8456162 | 0.85 | TRPA1 (0.33) | — | |
| SCHEMBL8456158 | 0.85 | TRPA1 (0.33) | — | |
| SCHEMBL8456167 | 0.85 | TRPA1 (0.33) | — | |
| SCHEMBL8835243 | 0.82 | TLR4 (0.32) | TLR4CYP2C9 | |
| SCHEMBL8835249 | 0.82 | TLR4 (0.32) | TLR4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409441-B1 | INDANE COMPOUNDS WITH NEGATIVE DIELECTRIC ANISOTROPY | MERCK PATENT GMBH (DE) | 2009-11-18 | — | — | EP | disclosed |
| US-7122228-B2 | Transistros; liquid crystals display; electrooptics | MERCK PATENT GMBH (DE) | 2006-10-17 | — | — | US | disclosed |
| US-20040171866-A1 | Transistros; liquid crystals display; electrooptics | MERCK PATENTGESELLSCHAFT (DE) | 2004-09-02 | — | — | US | disclosed |
| EP-1409441-A1 | INDANE COMPOUNDS WITH NEGATIVE DIELECTRIC ANISOTROPY | MERCK PATENT GmbH (DE) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003010120-A1 | INDANE COMPOUNDS WITH NEGATIVE DIELECTRIC ANISOTROPY | MERCK PATENT GMBH (DE) | 2003-02-06 | — | — | WO | disclosed |
| US-5662830-A | Diene derivative | CHISSO CORPORATION (JP) | 1997-09-02 | — | — | US | disclosed |
| US-5609791-A | Diene derivative | CHISSO CORPORATION (JP) | 1997-03-11 | — | — | US | disclosed |
| EP-0563982-B1 | Polycyclic diene derivatives | CHISSO CORP (JP) | 1996-07-17 | — | — | EP | disclosed |
| US-5449810-A | Diene derivative | CHISSO CORPORATION (JP) | 1995-09-12 | — | — | US | disclosed |
| EP-0563982-A2 | Polycyclic diene derivatives | Chisso Corporation (JP) | 1993-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171866-A1 | Transistros; liquid crystals display; electrooptics | VCL, RIF1, IPO11 | TLR4 2032/4885CYP2C9 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.